Table 3.
VOC identified by the CDC and the WHO for SARS‐CoV‐2
| Variant name | WHO label | Spike protein substitutions | Transmissibility | Immune evasiveness | Vaccine effectiveness | First detected In |
|---|---|---|---|---|---|---|
| B.1.1.7 | Alpha 31 , 39 | 69del,70del,144del, (E484K*),N501Y,A570D,D614G,P681H,T7161,S982A, D1118H (K1191N*) | + + + | _ _ | Yes | In the United Kingdom, September 2020 |
| B.1.351 | Beta 39 | D80A, D215G, 241del, 243del, K417N, E484K, N501Y, D614G, A701V | + | + + + + | Yes | in South Africa, May 2020 |
| B.1.617.2 | Delta 40 | T19R, (G142D*), 156del,R158G,L452R,T478K,D614,E484K,N501Y,D614G,A701V | + + + + | + + | Yes | In India, April 2021 |
| P.1 | Gamma 9 , 41 | L18F, T20N,P26S,D138Y,R190S,K4171T,E484K,N501Y,D614G,H655Y,T1027I | ++ | + + | Yes | In Japan/Brazil, November 2020 |
| B.1.429 | Epsilon 35 | S13I,W152C,L452R,L452R,D614 | + | + | Yes | In California, USA, March 2020 |
| B.1.427 | Epsilon 41 | L452R, D614 | + | + | Yes | In California, USA, March 2020 |
Abbreviations: CDC, Centers for Disease Control and Prevention; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2; VOC, variants of concern; WHO, World Health Organization.